An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.
CRC, Colorectal Cancer
DRUG: Tunlametinib combined with Fruquintinib
Progress Free Survival, Time from treatment beginning until disease progression, Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 6 weeks
Objecitve response rate, Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission, Evaluation of tumor burden based on RECIST criteria through study completion, an average of 6 weeks|Disease control rate, Proportion of patients who achieved a complete response, a partial response, or stable diseas, Evaluation of tumor burden based on RECIST criteria through study completion, an average of 6 weeks|Duration of Response, the time from the initial assessment of CR or PR for subjects with the best tumor efficacy to disease progression or death from any cause., Through study completion, an average of 3 weeks|Overall Survival, Time from treatment beginning until death from any cause, From date of treatment beginning until the date of death from any cause, through study completion, an average of 3 weeks|Incidence of Treatment-related adverse Events, Through study completion, an average of 3 weeks|Explore therapeutic efficacy biomarkers (including p-ERK levels, etc.), Before the subjects start the study treatment
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.